WaferGen Buys NGS Sample Prep Assets from IntegenX | GenomeWeb

NEW YORK (GenomeWeb News) — WaferGen Biosystems said today that it has acquired the next-generation sequencing library preparation business of IntegenX.

Under the agreement, WaferGen Inc., a subsidiary of WaferGen Biosystems, has acquired all of IntegenX's assets surrounding instruments and reagents related to NGS library preparation, including the Apollo 324 instrument and PrepX reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.